Cantor Fitzgerald initiated coverage of Context Therapeutics (CNTX) with an Overweight rating. Context is an under-the-radar oncology company developing three T-cell engagers, and as the company has been in execution mode, it is now approaching multiple data inflection points in 2026, the analyst tells investors in a research note. Lead program, CTIM-76, could prove to be a viable drug in ovarian cancer, the firm argues.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX: